Pfizer reported 83.7% slump in net profit to Rs 32.55 crore in Q1 FY23 as against Rs 199.91 crore posted in Q1 FY22.
Revenue from operations declined 20.9% year on year to Rs 592.90 crore in the quarter ended 30 June 2022. Profit before tax in Q1 FY23 stood at Rs 43.39 crore, up 83.9% from Rs 268.73 crore recorded in Q1 FY22.Total expenditure declined 12.5% YoY to Rs 431.20 crore during the quarter. Cost of materials consumed skid 4.5% to Rs 90.23 crore and employee benefits expenses slipped 2.3% to Rs 92.20 crore in Q1 FY23 over Q1 FY22.
Pfizer is a research-based global biopharmaceutical company which is engaged in the discovery, development and manufacture of healthcare products.
Shares of Pfizer closed 0.72% lower to end at Rs 4,230 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app